SCHEMBL20972782

SCHEMBL20972782

CC(C)CC(=O)CC(C=Cc1ccccc1)C(C(=O)O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.44
TDP1 Q9NUW8 2/20 0.39
HTT P42858 1/20 0.38
CNR2 P34972 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
HDAC3 O15379 4/20 0.38
HDAC4 P56524 4/20 0.38
HDAC1 Q13547 4/20 0.38
HDAC2 Q92769 4/20 0.38
HDAC8 Q9BY41 4/20 0.38
HDAC6 Q9UBN7 4/20 0.38
HDAC7 Q8WUI4 3/20 0.38
HDAC10 Q969S8 3/20 0.38
HDAC11 Q96DB2 3/20 0.38
HDAC9 Q9UKV0 3/20 0.38
HDAC5 Q9UQL6 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20972780 1.00 CYP1A2 (0.44) CYP1A2TDP1HTTCNR2ALDH1A1
SCHEMBL25611633 0.87 CYP1A2 (0.45) CYP1A2TDP1CNR2ALDH1A1CYP2C9
SCHEMBL22927463 0.86 CYP1A2 (0.42) CYP1A2TDP1HTTCNR2ALDH1A1
SCHEMBL20972779 0.85 ALDH1A1 (0.42) ALDH1A1GLALMNAHPGD
SCHEMBL20972778 0.85 ALDH1A1 (0.42) ALDH1A1GLALMNAHPGD
SCHEMBL23153423 0.85 CYP1A2 (0.41) CYP1A2TDP1HTTCNR2ALDH1A1
SCHEMBL22401208 0.84 TDP1 (0.42) CYP1A2TDP1ALDH1A1CYP3A4MAPK1
SCHEMBL28437449 0.84 TDP1 (0.42) CYP1A2TDP1ALDH1A1CYP3A4MAPK1
SCHEMBL20972773 0.84 CYP1A2 (0.35) CYP1A2TDP1CNR2ALDH1A1CYP2C19
SCHEMBL20972774 0.84 CYP1A2 (0.35) CYP1A2TDP1CNR2ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270158-A1 PROCESS FOR PREPARING TAPINAROF Dermavant Sciences GmbH (CH) 2025-08-28 US disclosed
US-12275696-B2 Process for preparing tapinarof Dermavant Sciences GmbH (CH) 2025-04-15 US disclosed
CN-111511357-B Process for preparing tazicar 德玛万科学有限责任公司 2024-04-09 CN disclosed
US-20230174445-A1 PROCESS FOR PREPARING TAPINAROF Dermavant Sciences GmbH (CH) 2023-06-08 US disclosed
US-11597692-B2 Process for preparing tapinarof Dermavant Sciences GmbH (CH) 2023-03-07 US disclosed
US-20210163388-A1 PROCESS FOR PREPARING TAPINAROF DERMAVENT SCIENCES GMBH (CH) 2021-06-03 US disclosed
US-10961175-B2 Process for preparing tapinarof Dermavant Sciences GmbH (CH) 2021-03-30 US disclosed
US-20210024442-A1 PROCESS FOR PREPARING TAPINAROF DERMAVENT SCIENCES GMBH (CH) 2021-01-28 US disclosed
EP-3706725-A1 PROCESS FOR PREPARING TAPINAROF Dermavant Sciences GmbH (CH) 2020-09-16 EP disclosed
CN-111511357-A Process for the preparation of talofu 德玛万科学有限责任公司 2020-08-07 CN disclosed
US-10647649-B2 Process for preparing tapinarof Dermavant Sciences GmbH (CH) 2020-05-12 US disclosed
US-20190144367-A1 PROCESS FOR PREPARING TAPINAROF DERMAVENT SCIENCES GMBH (CH) 2019-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024442-A1 PROCESS FOR PREPARING TAPINAROF TALDO1, TTR, CYP8B1 CYP1A2 134/4885TDP1 678/4885HTT 135/4885
US-20210163388-A1 PROCESS FOR PREPARING TAPINAROF TALDO1, TTR, CYP8B1 CYP1A2 134/4885TDP1 678/4885HTT 135/4885
US-20230174445-A1 PROCESS FOR PREPARING TAPINAROF TALDO1, TTR, CYP8B1 CYP1A2 134/4885TDP1 678/4885HTT 135/4885
US-10961175-B2 Process for preparing tapinarof TALDO1, TTR, CYP8B1 CYP1A2 134/4885TDP1 678/4885HTT 135/4885
US-10647649-B2 Process for preparing tapinarof TALDO1, TTR, CYP8B1 CYP1A2 134/4885TDP1 678/4885HTT 135/4885
US-12275696-B2 Process for preparing tapinarof TALDO1, TTR, CYP8B1 CYP1A2 134/4885TDP1 678/4885HTT 135/4885
US-20250270158-A1 PROCESS FOR PREPARING TAPINAROF TALDO1, TTR, CYP8B1 CYP1A2 134/4885TDP1 678/4885HTT 135/4885
US-20190144367-A1 PROCESS FOR PREPARING TAPINAROF TALDO1, TTR, CYP8B1 CYP1A2 134/4885TDP1 678/4885HTT 135/4885
US-11597692-B2 Process for preparing tapinarof TALDO1, TTR, CYP8B1 CYP1A2 134/4885TDP1 678/4885HTT 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.